Navigation Links
Vermillion Announces Additions to Commercial Management Team
Date:8/14/2014

AUSTIN, Texas, Aug. 14, 2014 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, has appointed David Jansen as Vice President of Marketing. In addition, the company has created the new position of Vice President of Sales and Managed Markets, which will be filled and announced shortly.

David Jansen has been hired to the new position of Vice President of Marketing. David joins us from Myriad Genetics, where he has held senior marketing roles for the last seven years. David has an undergraduate degree from Northern Arizona University and an MBA from the University of Phoenix.

"A major goal of Vermillion in 2014 is to take full control of our commercial progression as we re-define our strategic relationship with Quest," said James LaFrance, Vermillion's Chairman, President and Chief Executive Officer. "We have expanded our direct sales force, opened our new commercial CLIA lab, ASPiRA LABS, and are now supplementing our management team with critical commercial expertise and experience. David Jansen's expert knowledge of the women's health market with an industry leader, and his twenty years of global commercial marketing strategy expertise will be a tremendous asset for Vermillion. We will also soon be in a position to announce our new Vice President of Sales and Managed Markets who will be responsible for leading our direct selling efforts to health care professionals and all reimbursement efforts with commercial payers."

Both positions will report directly to the Chief Executive Officer. As part of this re-organization and re-structure, Marian Sacco, the Company's Chief Commercial Officer, will be leaving the Company.  Ms. Sacco joined Vermillion in December of 2013.

About Vermillion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in gynecologic oncology and women's health.

The company's lead diagnostic, OVA1®, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach. As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit www.vermillion.com.

About ASPiRA LABS
ASPiRA LABS is an innovative diagnostic services laboratory founded by Vermillion, Inc., a leader in women's health diagnostics. The laboratory's goal is to provide high quality, innovative testing for women to help address unmet women's health needs. ASPiRA LABS' specialized services are grounded in evidence-based medicine, while providing access to novel biomarker diagnostic tools designed to help health care professionals offer the most precise diagnoses and treatment guidance for their patients. To learn more about ASPiRA LABS, visit www.aspiralab.com.

Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements regarding the roles of the Vice President of Sales and Managed Markets and Vice President of Marketing. These forward-looking statements are based on Vermillion's expectations as of the date of this press release. A variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements, including the factors that are described in Vermillion's Form 10-K for the year ended December 31, 2013 and Vermillion's Form 10-Q for the quarter ended March 31, 2014 filed with the Securities and Exchange Commission.  Vermillion expressly disclaims any obligation to update, amend or clarify any forward-looking statements to reflect events, new information or circumstances occurring after the date of this press release, except as required by law.

Investor Relations Contact:
Eric Schoen
Vice President, Finance and Chief Accounting Officer
Tel 512-519-0424
eschoen@vermillion.com


'/>"/>
SOURCE Vermillion, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014
2. Vermillion Completes $17.6 Million Warrant Exercise
3. Vermillion Appoints Marian E. Sacco as SVP of Sales and Marketing and Chief Commercial Officer
4. Vermillion Reports Third Quarter 2013 Results
5. American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillions OVA1 Test in Presurgical Detection of Early-Stage Ovarian Cancer
6. American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillions Ovarian Cancer Test, OVA1
7. Vermillion Sets Third Quarter 2013 Conference Call for Thursday, November 14, 2013
8. Vermillion Appoints Dr. Eric Varma to its Board of Directors
9. Vermillion Supports First World Ovarian Cancer Day and Effort to Raise Awareness of the Need for Better Diagnosis and Treatment
10. Vermillion Sets First Quarter 2013 Conference Call for Wednesday, May 15, 2013
11. Vermillion Appoints Thomas McLain as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... -- Story Highlights: , ... health care industry is causing providers to review operating ... offers a suite of solutions for health care providers ... optimization: labor resource analysis, revenue cycle optimization and physician ... and better economics ...
(Date:6/24/2016)... 2016   Bay Area Lyme Foundation , ... Center for Tick Borne Illness , Harvard Medical ... Hacking Medicine, University of California, Berkeley, and the ... five finalists of Lyme Innovation , the ... 100 scientists, clinicians, researchers, entrepreneurs, and investors from ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
Breaking Medicine News(10 mins):